(Q37831334)

24 August 2017

1 reference

title

Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? (English)

1 reference

24 August 2017

0 references

0 references

Dimitri P Mikhailidis

series ordinal

3

object named as

Dimitri P Mikhailidis

1 reference

24 August 2017

Niki Katsiki

1

1 reference

24 August 2017

Apostolos I Hatzitolios

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

24 January 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

43

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

249-258

1 reference

Medical Consequences of Obesity

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Obesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Management of Obesity in Adults: European Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Clinical practice. Nonsurgical management of obesity in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Bariatric surgery for morbid obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

The epidemiology of obesity: the size of the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Bariatric surgery: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Antiobesity surgery in Sweden from 1980 to 2005: a population-based study with a focus on mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Investigational therapies in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

A review of the metabolic effects of sibutramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Lifestyle and pharmacological approaches to weight loss: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

The role of endocannabinoid system blockade in the treatment of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

The future of endocannabinoid-oriented clinical research after CB1 antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Withdrawal of sibutramine for weight loss: where does this leave clinicians?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Orlistat-associated adverse effects and drug interactions: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Rational design of a combination medication for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Naltrexone for the treatment of obesity: review and update

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Bupropion: a review of its use in the management of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Multiple actions of high-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

The role of statins for the primary and secondary prevention of coronary heart disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2010.541490

10.3109/07853890.2010.541490

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference